ALLOPURINOL TABLETS, USP

/ALLOPURINOL TABLETS, USP
ALLOPURINOL TABLETS, USP2018-09-06T09:12:40+00:00

Prescription Drug Name:

ALLOPURINOL TABLETS, USP

ID:

650758b1-f14f-ea48-e053-2a91aa0a7b3d

Code:

34391-3

DESCRIPTION


id: 650758b1-f151-ea48-e053-2a91aa0a7b3d
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Allopurinol has the following structural formula: Allopurinol is known chemically as 1,5-dihydro-4
H-pyrazolo [3,4-
d]pyrimidin-4-one. It is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. Each scored orange tablet contains 300 mg allopurinol and the inactive ingredients colloidal silicon dioxide, FD&C Yellow No. 6 Lake, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. Its solubility in water at 37°C is 80 mg/dL and is greater in an alkaline solution.

CLINICAL PHARMACOLOGY


id: 650758b1-f152-ea48-e053-2a91aa0a7b3d
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol for treatment of hyperuricemia is usually in the range of 0.3 to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol. These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL). The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of nephrolithiasis. Xanthine crystalluria has been reported in only three patients. Two of the patients had Lesch-Nyhan syndrome, which is characterized by excessive uric acid production combined with a deficiency of the enzyme, hypoxanthineguanine phosphoribosyltransferase (HGPRTase). This enzyme is required for the conversion of hypoxanthine, xanthine, and guanine to their respective nucleotides. The third patient had lymphosarcoma and produced an extremely large amount of uric acid because of rapid cell lysis during chemotherapy. Allopurinol is approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for allopurinol and oxipurinol respectively. After a single oral dose of 300 mg allopurinol, maximum plasma levels of about 3 mcg/mL of allopurinol and 6.5 mcg/mL of oxipurinol are produced. Approximately 20% of the ingested allopurinol is excreted in the feces. Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours. Oxipurinol, however, has a longer plasma half-life (approximately 15 hours) and therefore effective xanthine oxidase inhibition is maintained over a 24-hour period with single daily doses of allopurinol. Whereas allopurinol is cleared essentially by glomerular filtration, oxipurinol is reabsorbed in the kidney tubules in a manner similar to the reabsorption of uric acid. The clearance of oxipurinol is increased by uricosuric drugs, and as a consequence, the addition of a uricosuric agent reduces to some degree the inhibition of xanthine oxidase by oxipurinol and increases to some degree the urinary excretion of uric acid. In practice, the net effect of such combined therapy may be useful in some patients in achieving minimum serum uric acid levels provided the total urinary uric acid load does not exceed the competence of the patient’s renal function. Hyperuricemia may be primary, as in gout, or secondary to diseases such as acute and chronic leukemia, polycythemia vera, multiple myeloma, and psoriasis. It may occur with the use of diuretic agents, during renal dialysis, in the presence of renal damage, during starvation or reducing diets, and in the treatment of neoplastic disease where rapid resolution of tissue masses may occur. Asymptomatic hyperuricemia is not an indication for treatment with allopurinol (see
INDICATIONS AND USAGE ).
Gout is a metabolic disorder which is characterized by hyperuricemia and resultant deposition of monosodium urate in the tissues, particularly the joints and kidneys. The etiology of this hyperuricemia is the overproduction of uric acid in relation to the patient’s ability to excrete it. If progressive deposition of urates is to be arrested or reversed, it is necessary to reduce the serum uric acid level below the saturation point to suppress urate precipitation. Administration of allopurinol generally results in a fall in both serum and urinary uric acid within two to three days. The degree of this decrease can be manipulated almost at will since it is dose-dependent. A week or more of treatment with allopurinol may be required before its full effects are manifested; likewise, uric acid may return to pretreatment levels slowly (usually after a period of seven to ten days following cessation of therapy). This reflects primarily the accumulation and slow clearance of oxipurinol. In some patients a dramatic fall in urinary uric acid excretion may not occur, particularly in those with severe tophaceous gout. It has been postulated that this may be due to the mobilization of urate from tissue deposits as the serum uric acid level begins to fall. The action of allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of allopurinol to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs. Allopurinol can substantially reduce serum and urinary uric acid levels in previously refractory patients even in the presence of renal damage serious enough to render uricosuric drugs virtually ineffective. Salicylates may be given conjointly for their antirheumatic effect without compromising the action of allopurinol. This is in contrast to the nullifying effect of salicylates on uricosuric drugs. Allopurinol also inhibits the enzymatic oxidation of mercaptopurine, the sulfur-containing analogue of hypoxanthine, to 6-thiouric acid. This oxidation, which is catalyzed by xanthine oxidase, inactivates mercaptopurine. Hence, the inhibition of such oxidation by allopurinol may result in as much as a 75% reduction in the therapeutic dose requirement of mercaptopurine when the two compounds are given together.

INDICATIONS AND USAGE


id: 650758b1-f153-ea48-e053-2a91aa0a7b3d
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see
CLINICAL PHARMACOLOGY ,
CONTRAINDICATIONS ,
WARNINGS , and
PRECAUTIONS ).
Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.
the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.

CONTRAINDICATIONS


id: 650758b1-f154-ea48-e053-2a91aa0a7b3d
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Patients who have developed a severe reaction to allopurinol should not be restarted on the drug.

WARNINGS


id: 650758b1-f155-ea48-e053-2a91aa0a7b3d
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

ALLOPURINOL SHOULD BE DISCONTINUED AT THE FIRST APPEARANCE OF SKIN RASH OR OTHER SIGNS WHICH MAY INDICATE AN ALLERGIC REACTION. In some instances a skin rash may be followed by more severe hypersensitivity reactions such as exfoliative, urticarial, and purpuric lesions, as well as Stevens-Johnson syndrome (erythema multiforme exudativum), and/or generalized vasculitis, irreversible hepatotoxicity and, on rare occasions, death. In patients receiving PURINETHOL
® (mercaptopurine) or IMURAN
® (azathioprine), the concomitant administration of 300 to 600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see
CLINICAL PHARMACOLOGY ).
A few cases of reversible clinical hepatotoxicity have been noted in patients taking allopurinol, and in some patients, asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed. If anorexia, weight loss, or pruritus develop in patients on allopurinol, evaluation of liver function should be part of their diagnostic workup. In patients with pre-existing liver disease, periodic liver function tests are recommended during the early stages of therapy. Due to the occasional occurrence of drowsiness, patients should be alerted to the need for due precaution when engaging in activities where alertness is mandatory. The occurrence of hypersensitivity reactions to allopurinol may be increased in patients with decreased renal function receiving thiazides and allopurinol concurrently. For this reason, in this clinical setting, such combinations should be administered with caution and patients should be observed closely.

ADVERSE REACTIONS


id: 650758b1-f157-ea48-e053-2a91aa0a7b3d
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Data upon which the following estimates of incidence of adverse reactions are made are derived from experiences reported in the literature, unpublished clinical trials and voluntary reports since marketing of allopurinol began. Past experience suggested that the most frequent event following the initiation of allopurinol treatment was an increase in acute attacks of gout (average 6% in early studies). An analysis of current usage suggests that the incidence of acute gouty attacks has diminished to less than 1%. The explanation for this decrease has not been determined but may be due in part to initiating therapy more gradually (see
PRECAUTIONS and
DOSAGE AND ADMINISTRATION ).
The most frequent adverse reaction to allopurinol is skin rash. Skin reactions can be severe and sometimes fatal. Therefore, treatment with allopurinol should be discontinued immediately if a rash develops (see
WARNINGS ). Some patients with the most severe reaction also had fever, chills, arthralgias, cholestatic jaundice, eosinophilia and mild leukocytosis or leukopenia. Among 55 patients with gout treated with allopurinol for 3 to 34 months (average greater than 1 year) and followed prospectively, Rundles observed that 3% of patients developed a type of drug reaction which was predominantly a pruritic maculopapular skin eruption, sometimes scaly or exfoliative. However, with current usage, skin reactions have been observed less frequently than 1%. The explanation for this decrease is not obvious. The incidence of skin rash may be increased in the presence of renal insufficiency. The frequency of skin rash among patients receiving ampicillin or amoxicillin concurrently with allopurinol has been reported to be increased (see
PRECAUTIONS ).
Most Common Reactions* Probably Causally Related Gastrointestinal:  diarrhea, nausea, alkaline phosphatase increase, SGOT/SGPT increase Metabolic and Nutritional:  acute attacks of gout Skin and Appendages:  rash, maculopapular rash *Early clinical studies and incidence rates from early clinical experience with allopurinol suggested that these adverse reactions were found to occur at a rate of greater than 1%. The most frequent event observed was acute attacks of gout following the initiation of therapy. Analyses of current usage suggest that the incidence of these adverse reactions is now less than 1%. The explanation for this decrease has not been determined, but it may be due to following recommended usage (see 
ADVERSE REACTIONS introduction,
INDICATIONS AND USAGE ,
PRECAUTIONS , and
DOSAGE AND ADMINISTRATION ).
Incidence Less Than 1% Probably Causally Related Body As a Whole:  ecchymosis, fever, headache Cardiovascular:  necrotizing angiitis, vasculitis Gastrointestinal:  hepatic necrosis, granulomatous hepatitis, hepatomegaly, hyperbilirubinemia, cholestatic jaundice, vomiting, intermittent abdominal pain, gastritis, dyspepsia Hemic and Lymphatic:  thrombocytopenia, eosinophilia, leukocytosis, leukopenia Musculoskeletal:  myopathy, arthralgias Nervous:  peripheral neuropathy, neuritis, paresthesia, somnolence Respiratory:  epistaxis Skin and Appendages:  erythema multiforme exudativum (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome), hypersensitivity vasculitis, purpura, vesicular bullous dermatitis, exfoliative dermatitis, eczematoid dermatitis, pruritus, urticaria, alopecia, onycholysis, lichen planus Special Senses:  taste loss/perversion Urogenital:  renal failure, uremia (see
PRECAUTIONS )
Incidence Less Than 1% Causal Relationship Unknown Body As a Whole:  malaise Cardiovascular:  pericarditis, peripheral vascular disease, thrombophlebitis, bradycardia, vasodilation Endocrine:  infertility (male), hypercalcemia, gynecomastia (male) Gastrointestinal:  hemorrhagic pancreatitis, gastrointestinal bleeding, stomatitis, salivary gland swelling, hyperlipidemia, tongue edema, anorexia Hemic and Lymphatic:  aplastic anemia, agranulocytosis, eosinophilic fibrohistiocytic lesion of bone marrow, pancytopenia, prothrombin decrease, anemia, hemolytic anemia, reticulocytosis, lymphadenopathy, lymphocytosis Musculoskeletal:  myalgia Nervous:  optic neuritis, confusion, dizziness, vertigo, foot drop, decrease in libido, depression, amnesia, tinnitus, asthenia, insomnia Respiratory:  bronchospasm, asthma, pharyngitis, rhinitis Skin and Appendages:  furunculosis, facial edema, sweating, skin edema Special Senses:  cataracts, macular retinitis, iritis, conjunctivitis, amblyopia Urogenital:  nephritis, impotence, primary hematuria, albuminuria

To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email drugsafety@avkare.com ; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

OVERDOSAGE


id: 650758b1-f158-ea48-e053-2a91aa0a7b3d
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Massive overdosing or acute poisoning by allopurinol has not been reported. In mice, the 50% lethal dose (LD
50) is 160 mg/kg given intraperitoneally (I.P.) with deaths delayed up to five days and 700 mg/kg orally (p.o.) (approximately 140 times the usual human dose) with deaths delayed up to three days. In rats, the acute LD
50 is 750 mg/kg I.P. and 6000 mg/kg p.o. (approximately 1200 times the human dose).
In the management of overdosage there is no specific antidote for allopurinol. There has been no clinical experience in the management of a patient who has taken massive amounts of allopurinol. Both allopurinol and oxipurinol are dialyzable; however, the usefulness of hemodialysis or peritoneal dialysis in the management of an overdose of allopurinol is unknown.

DOSAGE AND ADMINISTRATION


id: 650758b1-f159-ea48-e053-2a91aa0a7b3d
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

The dosage of allopurinol to accomplish full control of gout and to lower serum uric acid to normal or near-normal levels varies with the severity of the disease. The average is 200 to 300 mg/day for patients with mild gout and 400 to 600 mg/day for those with moderately severe tophaceous gout. The appropriate dosage may be administered in divided doses or as a single equivalent dose with the 300 mg tablet. Dosage requirements in excess of 300 mg should be administered in divided doses. The minimal effective dosage is 100 to 200 mg daily and the maximal recommended dosage is 800 mg daily. To reduce the possibility of flare-up of acute gouty attacks, it is recommended that the patient start with a low dose of allopurinol (100 mg daily) and increase at weekly intervals by 100 mg until a serum uric acid level of 6 mg/dL or less is attained but without exceeding the maximal recommended dosage. Normal serum urate levels are usually achieved in one to three weeks. The upper limit of normal is about 7 mg/dL for men and postmenopausal women and 6 mg/dL for premenopausal women. Too much reliance should not be placed on a single serum uric acid determination since, for technical reasons, estimation of uric acid may be difficult. By selecting the appropriate dosage and, in certain patients, using uricosuric agents concurrently, it is possible to reduce serum uric acid to normal or, if desired, to as low as 2 to 3 mg/dL and keep it there indefinitely. While adjusting the dosage of allopurinol in patients who are being treated with colchicine and/or anti-inflammatory agents, it is wise to continue the latter therapy until serum uric acid has been normalized and there has been freedom from acute gouty attacks for several months. In transferring a patient from a uricosuric agent to allopurinol, the dose of the uricosuric agent should be gradually reduced over a period of several weeks and the dose of allopurinol gradually increased to the required dose needed to maintain a normal serum uric acid level. It should also be noted that allopurinol is generally better tolerated if taken following meals. A fluid intake sufficient to yield a daily urinary output of at least two liters and the maintenance of a neutral or, preferably, slightly alkaline urine are desirable. Since allopurinol and its metabolites are primarily eliminated only by the kidney, accumulation of the drug can occur in renal failure, and the dose of allopurinol should consequently be reduced. With a creatinine clearance of 10 to 20 mL/min, a daily dosage of 200 mg of allopurinol is suitable. When the creatinine clearance is less than 10 mL/min, the daily dosage should not exceed 100 mg. With extreme renal impairment (creatinine clearance less than 3 mL/min) the interval between doses may also need to be lengthened. The correct size and frequency of dosage for maintaining the serum uric acid just within the normal range is best determined by using the serum uric acid level as an index. For the prevention of uric acid nephropathy during the vigorous therapy of neoplastic disease, treatment with 600 to 800 mg daily for two or three days is advisable together with a high fluid intake. Otherwise similar considerations to the above recommendations for treating patients with gout govern the regulation of dosage for maintenance purposes in secondary hyperuricemia. The dose of allopurinol recommended for management of recurrent calcium oxalate stones in hyperuricosuric patients is 200 to 300 mg/day in divided doses or as the single equivalent. This dose may be adjusted up or down depending upon the resultant control of the hyperuricosuria based upon subsequent 24 hour urinary urate determinations. Clinical experience suggests that patients with recurrent calcium oxalate stones may also benefit from dietary changes such as the reduction of animal protein, sodium, refined sugars, oxalate-rich foods, and excessive calcium intake, as well as an increase in oral fluids and dietary fiber. Children, 6 to 10 years of age, with secondary hyperuricemia associated with malignancies may be given 300 mg allopurinol daily while those under 6 years are generally given 150 mg daily. The response is evaluated after approximately 48 hours of therapy and a dosage adjustment is made if necessary.

HOW SUPPLIED


id: 650758b1-f15a-ea48-e053-2a91aa0a7b3d
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

100 mg (white) scored, flat-faced beveled edge round tablets debossed with “2083/V”.

NDC 50268-063-15   (10 tablets per card, 5 cards per carton). 300 mg (orange) scored, round tablets debossed with “2084/V”.

NDC 50268-064-15   (10 tablets per card, 5 cards per carton).

Dispensed in Unit Dose Package.  For Institutional Use Only.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


id: 650758b1-f15c-ea48-e053-2a91aa0a7b3d
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

NDC 50268-063-15

Allopurinol Tablets, USP

100 mg

Rx Only

50 Tablets (5 x 10) Unit Dose

5026806315

NDC 50268-063-15

Allopurinol Tablets, USP

100 mg

Rx Only

50 Tablets (5 x 10) Unit Dose

5026806315

EACH TABLET CONTAINS:

Allopurinol, USP ……………………………………………. 100 mg

USUAL DOSAGE: See package insert for full prescribing information. DISPENSE in a tight, light-resistant container as defined in the USP.

STORE at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Manufactured for:

AvKARE, Inc.

Pulaski, TN 38478 AvPAK

A PRODUCT of AvKARE

Mfg. Rev. 11/07         AV 07/16 (P)

NDC 50268-064-15

Allopurinol Tablets, USP

300 mg

Rx Only

50 Tablets (5 x 10) Unit Dose

5026806415

NDC 50268-064-15

Allopurinol Tablets, USP

300 mg

Rx Only

50 Tablets (5 x 10) Unit Dose

5026806415 

EACH TABLET CONTAINS:

Allopurinol, USP ……………………………………………. 300 mg

USUAL DOSAGE: See package insert for full prescribing information. DISPENSE in a tight, light-resistant container as defined in the USP.

STORE at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Manufactured for:

AvKARE, Inc.

Pulaski, TN 38478 AvPAK

A PRODUCT of AvKARE

Mfg. Rev. 11/07         AV 07/16 (P)